Skip to main content

Table 1 Patient demographics and characteristics

From: Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma

Patient No. ECOG PS Histological subtype Stage Primary site Metastatic site Previous DOX chemotherapy Response PFS (Months)
1 0 Epithelioid sarcoma IV Extremities Lung and bone Yes PR 6
2 1 Epithelioid sarcoma IV Extremities Lung and lymph nodes Yes PR 11
3 1 Epithelioid sarcoma IV Extremities Lung and bone Yes PR 6
4 0 Epithelioid sarcoma IV Extremities Bone Yes SD 9
5 1 Epithelioid sarcoma IV Extremities Lung Yes PD 1.5
6 1 Angiosarcoma IV Extremities Bone Yes CR 12
7 0 Angiosarcoma IV Extremities Lung Yes SD 8
8 0 Angiosarcoma IV Extremities Lung Yes PR 7
9 0 Rhabdomyosarcoma IV Head Lung and Soft tissue Yes PR 9
10 0 Rhabdomyosarcoma IV Trunk Bone Yes SD 6
11 0 Rhabdomyosarcoma IV Extremities Lung Yes PD 3
12 1 UPS IV Extremities Lung Yes SD 6
13 0 UPS IV Pelvis Lung Yes PD 1.3
14 1 Fibrosarcoma IV Trunk Lung Yes PR 9
15 0 Fibrosarcoma IV Extremities Lung Yes PD 1
16 0 Leiomyosarcoma IV Extremities Lung Yes PD 2
17 1 PNET IV Trunk Lung Yes SD 3
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, UPS Undifferentiated pleomorphic sarcoma, PNET Primitive neuroectodermal tumor, DOX Doxorubicin-based, PR Partial response, SD Stable disease, PD Progressive disease, CR Complete response. PFS Progression-free survival